Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$15.12 USD
+0.39 (2.65%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $15.12 0.00 (0.00%) 5:22 PM ET
4-Sell of 5 4
B Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 138 | 298 | 191 | 140 | 95 |
Receivables | 54 | 10 | 7 | 6 | 11 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 7 | 8 | 5 | 2 |
Other Current Assets | 13 | 5 | 4 | 8 | 4 |
Total Current Assets | 219 | 321 | 210 | 159 | 111 |
Net Property & Equipment | 1 | 1 | 1 | 0 | 0 |
Investments & Advances | 16 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 37 | 19 | 24 | 33 | 0 |
Intangibles | 194 | 32 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 470 | 376 | 238 | 192 | 112 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 4 | 3 | 4 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 61 | 54 | 24 | 19 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 76 | 58 | 27 | 23 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 14 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 82 | 75 | 31 | 23 | 25 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 266 | 250 | 233 | 223 | 216 |
Retained Earnings | 121 | 50 | -26 | -54 | -129 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 388 | 300 | 207 | 170 | 88 |
Total Liabilities & Shareholder's Equity | 470 | 376 | 238 | 192 | 112 |
Total Common Equity | 388 | 300 | 207 | 170 | 88 |
Shares Outstanding | 117.50 | 104.00 | 103.10 | 103.60 | 103.00 |
Book Value Per Share | 3.30 | 2.89 | 2.01 | 1.64 | 0.85 |
Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 138 | 121 | 179 | 148 |
Receivables | NA | 54 | 48 | 43 | 33 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 16 | 9 | 11 | 10 |
Other Current Assets | NA | 13 | 14 | 9 | 7 |
Total Current Assets | NA | 219 | 192 | 241 | 199 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 16 | 13 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 37 | 37 | 23 | 20 |
Intangibles | NA | 194 | 167 | 176 | 184 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 470 | 413 | 444 | 407 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 15 | 5 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 61 | 53 | 48 | 53 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 76 | 58 | 53 | 57 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 13 | 13 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 82 | 65 | 69 | 74 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 266 | 262 | 258 | 254 |
Retained Earnings | NA | 121 | 86 | 117 | 79 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 388 | 349 | 375 | 334 |
Total Liabilities & Shareholder's Equity | NA | 470 | 413 | 444 | 407 |
Total Common Equity | 0 | 388 | 349 | 375 | 334 |
Shares Outstanding | 117.80 | 117.50 | 106.50 | 106.50 | 105.60 |
Book Value Per Share | 0.00 | 3.30 | 3.27 | 3.52 | 3.16 |